KRAS and familial pancreatic carcinoma: Again, on-target efficacy was suggested by the apparent lack of any therapeutic efficacy of BI-3406, Binimetinib, or radiation therapy as well as combination regimens in KRAS wild type BxPC3 pancreatic cancer cells (Figure 3e,f).